Literature DB >> 20211906

Increased frequency of HLA-DRB1*15 in patients with multifocal motor neuropathy.

N A Sutedja1, H G Otten, E A Cats, S Piepers, J H Veldink, W L van der Pol, L H van den Berg.   

Abstract

OBJECTIVES: The favorable response to treatment with IV immunoglobulins and the presence of IgM antibodies to the glycolipid GM1 are indications that inflammation underlies multifocal motor neuropathy (MMN) pathogenesis. We investigated the association of MMN with human leukocyte antigen (HLA) class I and II antigens.
METHODS: HLA class I and II antigens of 74 Dutch patients with MMN and 700 controls were determined in a case-control study. Associations of HLA types with MMN disease characteristics were investigated.
RESULTS: Compared with controls, patients with MMN had higher frequencies of HLA-DRB1*15 (41 vs 24%, p = 0.0017). Disease characteristics were not associated with specific HLA types.
CONCLUSIONS: Similar associations were found in patients with multiple sclerosis and women with chronic immune-mediated demyelinating neuropathy, which may suggest that these demyelinating disorders share pathogenic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211906     DOI: 10.1212/WNL.0b013e3181d3e2f6

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies.

Authors:  Lotte Vlam; W-Ludo van der Pol; Elisabeth A Cats; Dirk C Straver; Sanneke Piepers; Hessel Franssen; Leonard H van den Berg
Journal:  Nat Rev Neurol       Date:  2011-11-22       Impact factor: 42.937

Review 2.  The pathogenesis of multifocal motor neuropathy and an update on current management options.

Authors:  Jean-Marc Léger; Raquel Guimarães-Costa; Ruxandra Iancu Ferfoglia
Journal:  Ther Adv Neurol Disord       Date:  2015-05       Impact factor: 6.570

Review 3.  Immune pathogenesis and treatment of multifocal motor neuropathy.

Authors:  Lotte Vlam; Leonard H van den Berg; Elisabeth A Cats; Sanne Piepers; W-Ludo van der Pol
Journal:  J Clin Immunol       Date:  2012-09-02       Impact factor: 8.317

Review 4.  Intravenous immunoglobulin treatment in multifocal motor neuropathy.

Authors:  W-Ludo van der Pol; Elisabeth A Cats; Leonard H van den Berg
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

5.  Associated autoimmune diseases in patients with multifocal motor neuropathy and their family members.

Authors:  Elisabeth A Cats; Anne Suzanne Bertens; Jan H Veldink; Leonard H van den Berg; W Ludo van der Pol
Journal:  J Neurol       Date:  2011-11-23       Impact factor: 4.849

6.  Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15.

Authors:  Laura Martinez-Martinez; Ma Cinta Lleixà; Gemma Boera-Carnicero; Andrea Cortese; Jérôme Devaux; Ana Siles; Yusuf Rajabally; Alicia Martinez-Piñeiro; Alejandra Carvajal; Julio Pardo; Emilien Delmont; Shahram Attarian; Jordi Diaz-Manera; Ilaria Callegari; Enrico Marchioni; Diego Franciotta; Luana Benedetti; Guiseppe Lauria; Oscar de la Calle Martin; Cándido Juárez; Isabel Illa; Luis Querol
Journal:  J Neuroinflammation       Date:  2017-11-16       Impact factor: 8.322

7.  SMN1 Duplications Are Associated With Progressive Muscular Atrophy, but Not With Multifocal Motor Neuropathy and Primary Lateral Sclerosis.

Authors:  Jeroen W Bos; Ewout J N Groen; Renske I Wadman; Chantall A D Curial; Naomi N Molleman; Marinka Zegers; Paul W J van Vught; Reinier Snetselaar; Raymon Vijzelaar; W Ludo van der Pol; Leonard H van den Berg
Journal:  Neurol Genet       Date:  2021-06-22

Review 8.  Multifocal motor neuropathy: a review of pathogenesis, diagnosis, and treatment.

Authors:  Victoria H Lawson; W David Arnold
Journal:  Neuropsychiatr Dis Treat       Date:  2014-04-05       Impact factor: 2.570

9.  Abnormal nerve conduction study findings indicating the existence of peripheral neuropathy in multiple sclerosis and neuromyelitis optica.

Authors:  Yoko Warabi; Mikihiro Yamazaki; Toshio Shimizu; Masahiro Nagao
Journal:  Biomed Res Int       Date:  2013-11-07       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.